Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 28, 2015 1:07 PM ET

Pharmaceuticals

Company Overview of BioDiem Ltd.

Company Overview

BioDiem Limited, a biotechnology company, discovers, develops, and commercializes pharmaceutical and biomedical research for the treatment and prevention of cancers and infectious diseases. It offers Nasovac-S, a seasonal influenza vaccine based on live attenuated influenza virus technology. The company also engages in the expansion and development of vaccine technologies, including live attenuated influenza virus technology for use in seasonal and pandemic influenza vaccines; and antimicrobial BDM-I for the treatment of infectious diseases. In addition, it provides SAVINE antigen technology for the treatment of tuberculosis, Epstein Barr virus, HIV, and other diseases; flavivirus vaccine te...

100 Albert Road

Level 4

South Melbourne

Melbourne, VIC 3205

Australia

Phone:

61 3 9692 7222

Fax:

61 3 9077 9233

Key Executives for BioDiem Ltd.

Chief Executive Officer and Executive Director
Chief Financial Officer and Company Secretary
Age: 41
Compensation as of Fiscal Year 2014.

BioDiem Ltd. Key Developments

BioDiem Ltd. Auditor Raises 'Going Concern' Doubt

BioDiem Ltd. filed its Annual on Sep 30, 2014 for the period ending Jun 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

BioDiem Ltd., Annual General Meeting, Oct 23, 2014

BioDiem Ltd., Annual General Meeting, Oct 23, 2014., at 15:00 AUS Eastern Standard Time. Location: Grant Thornton, Wills Room, The Rialto, Level 30, 525 Collins Street. Agenda: To consider annual report for the financial year ending 30 June 2014; to consider re-election of Director, Hugh Matheson Morgan; and to consider re-election of Director Larisa Georgievna Rudenko.

BioDiem Ltd. Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

BioDiem Ltd. reported audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported revenue of $113,939 against $101,615 a year ago. Loss before income tax expense was $1,018,349 against $2,316,160 a year ago. Loss after income tax expense for the year attributable to the owners of the company was $1,018,349 against $2,316,160 a year ago. Net cash used in operating activities was $1,101,070 against $1,984,638 a year ago.

Similar Private Companies By Industry

Company Name Region
Delvet Pty Ltd. Asia
Otifex Therapeutics Pty. Ltd. Asia
PharmAust Manufacturing Pty., Ltd. Asia
Sypharma Pty. Ltd. Asia
4G Vaccines Pty Ltd. Asia

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioDiem Ltd., please visit www.biodiem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.